Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.
about
Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variantsA Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.Correlation between the efficacy of amrubicin and the previous chemotherapy regimen for relapsed small cell lung cancer.Folding graft copolymer with pendant drug segments for co-delivery of anticancer drugsReduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.Mechanisms of multidrug resistance in cancer treatment.Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients.Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.Nanodrug Formed by Coassembly of Dual Anticancer Drugs to Inhibit Cancer Cell Drug Resistance.Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.Resistance to chemotherapy in cancer: a complex and integrated cellular response.Genetic mechanisms of drug resistance. A review.Topoisomerases: Resistance versus Sensitivity, How Far We Can Go?Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel.Altered phosphorylation of topoisomerase I following overexpression in an ovarian cancer cell line.DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.Damage-sensing mechanisms in human cells after ionizing radiation.Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma.Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines.Lack of in vivo cross-resistance with 4'-thio-ara-C against drug-resistant murine P388 and L1210 leukemias.Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.Topoisomerase I amino acid substitutions, Gly185Arg and Asp325Glu, confer camptothecin resistance in Leishmania donovani.Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines.Methylated BNIP3 gene in colorectal cancer prognosis.Current perspectives on camptothecins in cancer treatmentCombined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?Dual topoisomerase I/II poisons as anticancer drugs.Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.
P2860
Q28361246-FA356F6F-6864-42C1-9048-8312CEFE4F37Q33344326-DD710E31-2646-40DF-879A-E2D9B6EF6EA1Q33599044-44E789F9-AC83-4F42-BCE8-6353897BDF5DQ33936160-490D0DD1-3E70-49DF-831F-CB56A5F2A375Q34385596-E0EAEEFB-6CE7-4A8E-A370-92C9E39EED53Q35259390-72ECF5C7-A66B-4E93-8441-2B7C1734E4B4Q35832549-6FD690FF-2C53-4EB1-935B-CEAE19FB15C9Q36422757-D1936AA8-0A60-4FF7-B1E8-C9467B3B44F0Q36431537-1C0C706E-CD67-46B0-B221-86E48B330393Q36461811-E3687EC0-1D2D-48F8-B6B7-323B656DB2D6Q36517999-88BE94AA-1ECD-446C-A36A-4EA10A287BEBQ37079652-503E3F25-87C7-4C75-AF54-1FEA63A4D829Q37679117-C0DAD0C3-AADE-41F9-8DCF-2D7D8266500FQ38968355-DC9529C5-D015-467B-BF85-EAE89230CEF9Q39998037-DF81878E-3880-4B32-92F5-3EED8E12EBE7Q40319756-210E937C-BD2C-497F-B224-F8D969B21A4FQ41094672-6ACB37B9-7678-480A-81E1-65BF523C88C9Q41137233-D2E3F98E-5759-410E-B259-F56C087A9E09Q41202524-BF662222-0DF0-4BC9-A75E-A44509D99D7BQ41317523-7AD699EC-DCF2-4CDA-8273-35122573C24DQ41339782-70A0FAAD-3ACD-41EE-BE1F-3FDF5B6B96E5Q41391609-EB0053B7-8D35-4763-87C2-59952DE93FD3Q41892199-15C1FE58-A57A-4BA6-9E65-E15D1C82B31AQ41985872-9C263112-4B06-4944-8A94-0D196915636AQ42204087-7ECD269C-BC06-4813-B2C7-6E3248228E55Q42279792-14B7956C-0FF2-4FA5-A9EF-9C1ED5DC54FCQ42323760-B3950AEF-941D-44E3-A229-B7FCE86652ADQ42715927-01055A53-1B72-495F-8513-CE59301D40B9Q43007521-44770438-6E17-45F2-BC4B-EF5DEEE9D1D9Q53668428-BB2D39CB-46EC-42BF-8A9C-D83E9BF3256EQ55033660-E20AC2F0-164F-4C02-AA95-DFE3D344ED6C
P2860
Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Nonproductive rearrangement of ...... e to topoisomerase inhibitors.
@en
Nonproductive rearrangement of ...... e to topoisomerase inhibitors.
@nl
type
label
Nonproductive rearrangement of ...... e to topoisomerase inhibitors.
@en
Nonproductive rearrangement of ...... e to topoisomerase inhibitors.
@nl
prefLabel
Nonproductive rearrangement of ...... e to topoisomerase inhibitors.
@en
Nonproductive rearrangement of ...... e to topoisomerase inhibitors.
@nl
P2093
P356
P1476
Nonproductive rearrangement of ...... e to topoisomerase inhibitors.
@en
P2093
P304
P356
10.1093/JNCI/81.22.1732
P407
P577
1989-11-01T00:00:00Z